In tumors that retain some responsiveness to conventional therapy, death-receptor engagement in combination with chemotherapy or irradiation might lead to synergistic apoptosis activation, and reduce the probability that tumor cells resistant to either type of agent will emerge. In tumors that have lost p53 function, death-receptor targeting might help to circumvent resistance to chemotherapy and radiotherapy (Ref.7, 8 & 9).